Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis |
| |
Authors: | Jean-Guy Boiteau Gilles Ouvry Jean-Marie Arlabosse Stéphanie Astri Audrey Beillard Yushma Bhurruth-Alcor Laetitia Bonnary Claire Bouix-Peter Karine Bouquet Marilyne Bourotte Isabelle Cardinaud Catherine Comino Benoît Deprez Denis Duvert Angélique Féret Feriel Hacini-Rachinel Craig S. Harris Anne-Pascale Luzy Laurent F. Hennequin |
| |
Affiliation: | 1. Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France;2. Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 – Drugs and Molecules for Living Systems, F-59000 Lille, France |
| |
Abstract: | Targeting the TNFα pathway is a validated approach to the treatment of psoriasis. In this pathway, TACE stands out as a druggable target and has been the focus of in-house research programs. In this article, we present the discovery of clinical candidate 26a. Starting from hits plagued with poor solubility or genotoxicity, 26a was identified through thorough multiparameter optimisation. Showing robust in vivo activity in an oxazolone-mediated inflammation model, the compound was selected for development. Following a polymorph screen, the hydrochloride salt was selected and the synthesis was efficiently developed to yield the API in 47% overall yield. |
| |
Keywords: | LZUHYMGQNXWOHQ-UHFFFAOYSA-N BQDVTMRZPWSYOT-UHFFFAOYSA-N TACE inhibitor Psoriasis Solubility Polymorph Aminonitrile synthesis |
本文献已被 ScienceDirect 等数据库收录! |
|